Immunotherapy: Open Access
Open Access
ISSN: 2471-9552
+44 1223 790975
ISSN: 2471-9552
+44 1223 790975
CIRI, International Center for Research in Infectiology, Team Vir Path, Univ Lyon, Inserm, France
Case Report
Immunity to SARS-CoV-2 in a Dialyzed Patient who Developed COVID-19 Twenty Days after the Second Dose of BNT162b2 Vaccine: A Case Report
Author(s): Sabrina Manni*, Laurène Lotte, Antonin Bal, Laurence Josset, Bruno Lina, Mary Anne Trabaud, Gregory Destras, Bruno Pozzetto, Martine Valette, Corinne Passeron, Barbara Seitz-Poslki, Audrey Sindt and Matteo Vassallo
Introduction: End stage kidney disease (ESKD) and cancer have been identified as risk factors for severe and
fatal cases of COVID-19, making vaccination in these patients a priority. Patients suffering from ESKD have a
significantly weaker response to common vaccines than general population. However, humoral and cellular immune
responses after two doses of RNA-based vaccine BNT162b2 (Pfizer–BioNTech) have been poorly explored in this
vulnerable population.
Case presentation: A 69-year-old male patient was followed for ESKD and myeloma treated with Daratumumab. He
developed a severe SARS-CoV-2 pneumonia treated with oxygen supplementation and dexamethasone twenty days
after two doses of BNT162b2 vaccine. Whole genome sequencing found that the virus belonged to the 20I/501Y.V1
clade. A serology draws eight days after t.. View More»
DOI:
10.35248/2471-9552.22.08.192